Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Palleon Pharmaceuticals

Palleon Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of E-602 (HLX79), a Potential First-In-Class Treatment for Active Glomerulonephritis
From Palleon Pharmaceuticals
Via Business Wire
Palleon Pharmaceuticals Announces NMPA IND Clearance to Proceed with Phase 2 Clinical Trial of E-602 (HLX79), a First-In-Class Treatment for Autoimmune Diseases
From Palleon Pharmaceuticals
Via Business Wire
Palleon Pharmaceuticals and Henlius Collaborate to Advance Glycan Editing as a Treatment for Autoimmune Diseases
From Palleon Pharmaceuticals
Via Business Wire
Palleon Pharmaceuticals Presents Results from the Phase 1/2 GLIMMER-01 Trial of E-602 in Combination with Cemiplimab in Patients with Solid Tumors at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Palleon Pharmaceuticals
Via Business Wire
Palleon to Present New Findings on Colorectal Tumor Microenvironment Identified with its HYDRA Platform at Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Palleon Pharmaceuticals
Via Business Wire
Palleon Pharmaceuticals Recognized as a Fierce Biotech “Fierce 15” Company for 2023
From Palleon Pharmaceuticals
Via Business Wire
Palleon Pharmaceuticals Announces First Patient Dosed with E-602 in Combination with Cemiplimab in GLIMMER-01 Phase 1/2 Clinical Trial
From Palleon Pharmaceuticals
Via Business Wire
Palleon Pharmaceuticals Presents Initial Phase 1 Results from the GLIMMER-01 Clinical Trial for E-602, the First Ever Glyco-Immune Checkpoint Inhibitor
From Palleon Pharmaceuticals
Via Business Wire
Palleon Pharmaceuticals to Present at the Guggenheim Healthcare Talks Oncology Day
From Palleon Pharmaceuticals
Via Business Wire
Palleon Announces Issuance of a U.S. Patent for Use of Antibody Sialidase Conjugates
From Palleon Pharmaceuticals
Via Business Wire
Palleon Pharmaceuticals to Present at the Oppenheimer Healthcare Private Company Showcase
From Palleon Pharmaceuticals
Via Business Wire
Palleon to Present on Phase 1/2 E-602 Bi-Sialidase Trial Design at Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Palleon Pharmaceuticals
Via Business Wire
Palleon Co-Founder Dr. Carolyn Bertozzi Awarded Nobel Prize in Chemistry for Pioneering Methods of Studying Glycobiology
From Palleon Pharmaceuticals
Via Business Wire
Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies
From Palleon Pharmaceuticals
Via Business Wire
Palleon Presents Preclinical Data on Lead Program E-602 and Novel Bifunctional PD-L1-Targeted Sialidase
From Palleon Pharmaceuticals
Via Business Wire
Palleon Pharmaceuticals Announces IND Clearance for First-in-Class Cancer Immunotherapy Leveraging Glyco-Immunology
From Palleon Pharmaceuticals
Via Business Wire
Palleon Pharmaceuticals Appoints Denis Patrick to Its Board of Directors
From Palleon Pharmaceuticals
Via Business Wire
Palleon Presents Data on Sialoglycan Degradation Platform That Enhances Anti-Tumor T-Cell Immunity
From Palleon Pharmaceuticals
Via Business Wire
Palleon Pharmaceuticals Appoints David Johnson to Its Board of Directors
From Palleon Pharmaceuticals
Via Business Wire
Palleon to Present Preclinical Data on Lead Immuno-Oncology Program, E-602, at SITC Annual Meeting
From Palleon Pharmaceuticals
Via Business Wire
Palleon Pharmaceuticals Appoints David Feltquate as Chief Medical Officer
From Palleon Pharmaceuticals
Via Business Wire
Palleon Pharmaceuticals Presents Data Suggesting Role of Hypersialylation in Metastatic Melanoma Patients’ Resistance to PD1 Inhibitors
From Palleon Pharmaceuticals
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.